REG - C4X Discovery - C4XD and Garvan Institute collaboration

C4X Discovery HoldingsAnnouncement

22/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230222:nRSV6219Qa&default-theme=true

RNS Number : 6219Q  C4X Discovery Holdings PLC  22 February 2023

C4XD and Garvan Institute of Medical Research report successful patient
stratification approach using C4XD's new precision medicine platform
PatientSeek

 

First validation of C4XD's patient sub-groups through a Garvan-led
retrospective clinical trial analysis

 

Promising initial result paves way for novel approaches in Parkinson's disease
stratification

 

Launch of PatientSeek platform enables stratification of patients to identify
the right patient for the right medicine

 

22 February 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces the launch of a precision medicine platform,
PatientSeek, following insights from a successful research collaboration with
Garvan Institute of Medical Research ("Garvan Institute").

 

In the collaboration, C4XD provided Garvan Institute with the genetic
signatures for its PatientSeek sub-groups in Parkinson's disease. Garvan
researchers then applied this as part of a retrospective analysis of a failed
Phase 3 Parkinson's clinical trial that had not reached its primary endpoint,
to assess if a genetic subgroup of participants showed a benefit from the
therapeutic.  Very encouragingly, PatientSeek identified a subgroup that
responded to the trial drug. These insights into Parkinson's disease have the
potential to help identify the most effective treatments and match them with
groups of patients who are most likely to benefit, accelerating the drug
development process.

 

These results provide the first validation of PatientSeek's ability to
identify patient subgroups to optimise patient selection, which in turn could
lead to enhanced probability of targeted success in clinical trials. Whilst
this study was focused on Parkinson's disease the PatientSeek platform is
disease agnostic and can be applied to any complex genetic disease. The
results from this study will be submitted for publication in a peer reviewed
journal in due course.

 

Garvan research partner, Associate Professor Antony Cooper, Research Director
of the Australian Parkinson's Mission, said: "This is a very important result
which not only demonstrates that subgroups derived with PatientSeek are
clinically relevant, but also reaffirms the important role that genetics play
in Parkinson's disease, including response to treatment. These findings have
wide-reaching implications for patients, clinicians and researchers, and have
advanced a key goal of the Australian Parkinson's Mission of expanding
precision medicine approaches to identify effective therapeutics for people
with Parkinson's disease. We will now focus on the mechanistic understanding
of the differences between the patient subgroups identified to accelerate our
understanding of the disease heterogeneity observed in Parkinson's disease".

 

Dr Richard Wyse, Director of Clinical Development at Cure Parkinson's who
introduced C4XD to Garvan Institute, said: "This work has enormous potential
and paves the way for novel approaches to stratify patients in disease
modifying Parkinson's trials. Such approaches could inform clinical trial
design, better select patients for their likelihood to be responders to
specific therapeutics, and help enable development of companion diagnostics.
This is a ground-breaking result and an important milestone in bringing
precision medicine to patients."

 

Dr Clare Murray, SVP Drug Discovery at C4XD, said: "Our new PatientSeek
platform is the result of a successful Taxonomy3® collaboration with Garvan
Institute. Taxonomy3® has historically been used for target identification,
but this study clearly demonstrates the potential to use PatientSeek to apply
our unique mathematical approach to stratify patients for novel treatments
based on their genetics. C4XD has already identified PatientSeek subgroups in
immuno-inflammatory disease and we will be exploring their application in
bringing precision medicine approaches to these patient populations."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 Garvan Institute of Medical Research                      +61 (0)480 391 269

 Carolyn Barry, Communications

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have three commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.  For further
information see www.c4xdiscovery.com (http://www.c4xdiscovery.com/)

 

About PatientSeek

PatientSeek, powered by Taxonomy3®, is C4XD's new platform for patient
stratification based on clinically relevant genetic subgroups of patients to
ensure the right drug is given to the right patient, based on their genetics.
PatientSeek has the potential to de-risk drug development by identifying
patient subgroups that are most likely to benefit from treatment and informing
development of companion diagnostics.

 

About Garvan Institute of Medical Research

Garvan Institute of Medical Research brings together world-leading researchers
and clinicians, collaborating locally and globally, to improve human
health. Its mission is to harness the information encoded in the human
genome to better diagnose, treat, predict and prevent disease. Through its
key scientific strengths in data, genomics, cellular, translational and
clinical science, Garvan aims to catalyse research from fundamental discovery
to transformational impact. Garvan values its strong partnerships, most
notably as a member of the St Vincent's Health Innovation Precinct, and as a
close collaborator with UNSW Sydney.

https://www.garvan.org.au (https://www.garvan.org.au)

 

About Cure Parkinson's

Cure Parkinson's is a UK-based charity that funds and facilitates research
into disease modifying therapies to slow, stop or even reverse Parkinson's.
https://cureparkinsons.org.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKDBNOBKDFBB